Effects of PRP, PPP, and BMAC on recovery after hip surgery for labral issues
Effect of Platelet-Rich Plasma, Platelet-Poor Plasma, & Bone Marrow Aspirate Concentrate Application on Functional Outcomes Following Hip Arthroscopy for Acetabular Labral Pathologies: A Prospective Randomized Controlled Trial
This study is testing whether treatments like platelet-rich plasma and bone marrow concentrate can help people recover better after hip surgery for labral issues.
Quick facts
| Phase | Phase 3 |
|---|---|
| Study type | Interventional |
| Enrollment | 160 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Massachusetts General Hospital Academic / other |
| Locations | 1 site (Boston, Massachusetts) |
| Trial ID | NCT06003101 on ClinicalTrials.gov |
What this trial studies
This clinical trial evaluates the impact of platelet-rich plasma (PRP), platelet-poor plasma (PPP), and bone marrow aspirate concentrate (BMAC) on functional recovery following hip arthroscopy for acetabular labral pathologies. The study aims to determine whether these treatments can enhance functional outcomes and reduce arthritic symptoms post-surgery. Participants will be randomly assigned to receive either the treatment or a control, with outcomes measured through validated functional assessments. The trial is designed to provide insights into optimizing surgical management of labral injuries.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 and older who require hip arthroscopy for labral pathology.
Not a fit: Patients who have had prior surgeries on the same hip or are non-English speakers may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved recovery and reduced pain for patients undergoing hip arthroscopy for labral pathologies.
How similar studies have performed: Previous studies have shown promising results with similar regenerative approaches, suggesting potential for success in this trial.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age: \> or equal to 18 years * Clinically indicated for hip arthroscopy (by the study PI) to address a labral pathology * Willingness to participate, amenable to randomization into either treatment arm of the research study, and the ability to understand \& sign the informed consent document Exclusion Criteria: * Non-English speaking (PROM surveys are only validated in English) * Prior same site (i.e., ipsilateral hip) surgery, including but not limited to previous hip arthroscopy, core decompression, or periacetabular osteotomies
Where this trial is running
Boston, Massachusetts
- Massachusetts General Hospital — Boston, Massachusetts, United States (Recruiting)
Study contacts
- Principal investigator: Scott D. Martin, MD — Massachusetts General Hospital
- Study coordinator: Scott D. Martin, MD
- Email: sdmartin@mgh.harvard.edu
- Phone: 617-732-5329
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.